Dear Editor:

We read the article by D'Amico et al[@bib1] discussing the pathogenesis, epidemiology, prevention, and management of diarrhea among patients with coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We agree on the importance of such reviews, primarily targeted to gastroenterologists. Nevertheless, we would like to discuss additional implications and analyses presented by D'Amico et al[@bib1] regarding the prevalence of diarrhea derived from available published studies, and its comparison with SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV) infections.

D'Amico et al[@bib1] analyzed in the results from 20 studies in Table 1 in their article, with a pooled prevalence of 10.4%, although no information on the meta-analysis model was provided. We used that data, and additionally included 11 novel studies, published through May 3, 2020, also assessing the frequency of diarrhea among COVID-19 patients. With a total of 3335 patients from 31 studies, we used random-effects and fixed-effects models to determine the pooled prevalence. We used the Open Meta-Analyst software (Providence, RI). For the random-effects model, we found that 13.8% of patients presented with diarrhea (95% CI, 10.6%--17.0%), and for the fixed-effects model, 6.1% presented with diarrhea (95% CI, 5.4%--6.9%) ([Figure 1](#fig1){ref-type="fig"} ). In the case of SARS-CoV and MERS-CoV, D'Amico et al[@bib1] did not provide pooled prevalences for comparisons with SARS-CoV-2. Then, we used the data D'Amico et al[@bib1] presented about these previous coronaviruses regarding diarrhea and we added 2 studies on SARS-CoV. Combining the data from 735 patients with SARS-CoV, the pooled prevalence yielded 12.4% (95 CI, 4.8%--20.0%) in the random-effects model, and 2.3% (95% CI, 1.3%--3.3%) in the fixed-effects model ([Figure 1](#fig1){ref-type="fig"}). In the case of MERS-CoV, this was 23.1% (95% CI, 10.7%--35.4%) and 17.5% (95% CI, 13.1%--21.9%), respectively ([Figure 1](#fig1){ref-type="fig"}).Figure 1Random-effects and fixed-effects model for the pooled prevalence of diarrhea among COVID-19 patients.[@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21]

In addition to the cohort, cross-sectional, and case series studies, D'Amico et al[@bib1] also included 3 case reports. We also looked at those and found 6 more case reports. Most of them are from China (5), followed by Japan (2), the United States (1), and Lebanon (1), with a median diarrhea duration of 3 days, with the number of evacuations ranging from 2 to 6 per day.[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7]

In a previous meta-analysis, we found that diarrhea was reported among 6.1% (95% CI, 2.4%--9.7%) of patients with COVID-19 (6 studies, 457 patients),[@bib8] which was the same prevalence obtained now with 31 studies and 3335 patients by the fixed-effects model in the current analysis ([Figure 1](#fig1){ref-type="fig"}). Although this would be considered a low prevalence, the COVID-19 pandemic has affected 10.49 million people worldwide (as of July 1, 2020), translating into between 566,897 and 724,368 diarrhea-associated cases (based on 95% CIs for pooled prevalence).

Because SARS-CoV-2 directly or indirectly may affect the enteric mucosa,[@bib1] diarrhea and other gastrointestinal findings should raise clinical suspicion for COVID-19, with or without the presence of fever, cough, and other respiratory and nonrespiratory manifestations.[@bib8]

Finally, as D'Amico et al[@bib1] mentioned, fecal--oral transmission may be an additional source of transmission that deserves more research and subsequent preventive interventions.
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